Navigation Links
Patient age not a factor in use of second-line therapy for lung cancer
Date:3/3/2010

Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

Lung cancer is the leading cause of cancer death in the world. Lung cancer incidence peaks between ages 70 and 80, and the mortality rate increases with age. EGFR-TKIs, such as gefitinib or erlotinib, are effective agents used in salvage therapy for NSCLC after patients have failed previous chemotherapy and have yielded a modest survival benefit. However, the majority of patients enrolled in these clinical trials using salvage therapy against NSCLC were younger than 70 years. Whether elderly patients are as suitable for salvage therapy as younger patients, and whether salvage targeted therapy is better or more tolerable than salvage chemotherapy in elderly patients are both unknown.

In this study, researchers retrospectively analyzed the data of 461 cases of nonelderly (under 70 years) and elderly (age 70 and older) patients with NSCLC who had failed previous chemotherapy and received salvage therapy. The treatment response rate, time to disease progression, overall survival time and toxicity profiles of the two groups were compared.

Elderly (>70 years)
Response Rate: 19%
Control Rate: 68%
Progression-free time: 4.4 months
Overall survival time: 9.3 months
One-year survival: 38%

Nonelderly (<70 years)
Response Rate: 24%
Control Rate: 68%
Progression-free time: 4.1 months
Overall survival time: 8.3 months
One-year survival: 41%

The nonelderly group had a similar response rate, control rate, and median survival time to the elderly group. In fact, the median progression-free time was numerically longer in the elderly than in the nonelderly patients. In addition, the use of EGFR-TKI salvage therapy, compared with salvage chemotherapies in the elderly group, resulted in a similar disease control rate and median survival time and more favorable toxicity profiles.

"In our study, we found there were no differences in the efficacy of salvage chemotherapies and EGFR-TKI therapy, in terms of response rate, control rate, and overall survival, in elderly and nonelderly patients, and the therapies had acceptable toxicities," said Chieh-Hung Wu, MD of Taipei Veterans General Hospital in Taiwan. "Age itself should not preclude patients with NSCLC from second-line salvage therapy with EGFR-TKIs. This is especially important as elderly patients are more easily frustrated when treatment for lung cancer fails and may refuse further salvage therapy."


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Lung cancer research explores the effects of patient attitudes on patient outcomes
2. Kidney Patients From Across South Carolina Visit State Capitol to Encourage Policies that Improve Patient Access to Life-Saving Dialysis and Transplant Care
3. Project Runways Tim Gunn Returns to Address Psoriasis(TM) and Empower Patients to be Confident in Their Personal Style
4. State payer mandates to cover cancer trials offer heterogeneous protection for patients
5. Death After Discharge Rates Higher in Elderly ICU Patients
6. New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association
7. The Right Colorectal Cancer Test for the Right Patient
8. Greenway Medical Technologies Advances Patient-Provider Benefits
9. Santa Rosa Consulting Announces New Free Education Series: Hot Topics in Patient Care Device Integration
10. Arizona Oncology Praises New Guidelines for Patient Care
11. Hospices not deactivating defibrillators in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: